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Abstract
Introduction: The Amplatzer septal occluder is frequently used for percutaneous closure of an atrial septal defect.
Complications include thrombosis and embolism, dislocation, cardiac perforation, and, rarely, infection. We report
the case of a patient who had survived an occluder-related thromboembolism two years previously.
Case presentation: A 72-year-old Caucasian woman had received a septal occluder because of an atrial septal
defect seven years ago. Two years ago, she underwent chemotherapy of a non-Hodgkin lymphoma, developed
atrial fibrillation, and experienced a left-sided occluder thrombosis with stroke and peripheral embolism. Now, she
presented with cerebral lymphoma, received glucocorticoids, and subsequently developed skin lesions. Swabs from
the lesions and blood cultures were positive for methicillin-resistant Staphylococcus aureus and Pseudomonas
aeruginosa. Endocarditis, however, was considered only two months later and echocardiography suggested aortic
valve endocarditis. Despite antibiotic therapy, she died three days later because of septicemia, and no post-mortem
investigation was carried out. It remains uncertain whether the septal occluder was endothelialized or infected and
whether explantation might have changed the outcome.
Conclusions: If infections occur in patients with a septal occluder, endocarditis should be considered and
echocardiography should be performed early. To prevent a fatal outcome, explantation of the septal occluder
should be considered, especially in patients with problems that suggest delayed endothelialization. Post-mortem
investigations, including bacteriologic studies, should be carried out in patients with a septal occluder in order to
assess the focal and global long-term effects of these devices.
Introduction
The Amplatzer septal occluder (SO) (AGA Medical Cor-
poration, Plymouth, MN, USA) is a frequently used
device for percutaneous closure of an atrial septal defect
(ASD). Complications of occluders include thrombosis
and embolism, dislocation, cardiac perforation, and,
rarely, infection [1-5]. We report the fatal course of sep-
ticemia in a patient who had already survived an SO-
related thromboembolism two years previously [6].
Case presentation
Our patient was a 72-year-old Caucasian woman who
had a hemodynamically relevant ASD and who at the
age of 65 years had received a 22 mm SO because of
increasing exertional dyspnea. She did not complain of
arrhythmia, and the results of a coronary angiography
were normal. The further course was complicated by a
non-Hodgkin lymphoma and probably by chemother-
apy-induced Evans syndrome. Symptomatic atrial fibril-
lation was diagnosed 58 months after implantation, and
a therapy with bisoprolol and acetylsalicylic acid was
started. Between 56 and 59 months after implantation, a
left-sided SO thrombosis developed, as demonstrated by
computed tomography [6]. The SO thrombosis led to
ischemic stroke and peripheral embolism, necessitating
surgical embolectomy in all extremities and oral anticoa-
gulation (OAC) with phenprocoumon. Complete disap-
pearance of the SO thrombus was demonstrated by
transesophageal echocardiography five months later.
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oagulants, elevation of homocysteine, and factor VIII).
At the age of 72 years, vertigo, headache, and visual
field defects occurred. Despite normal results of a cere-
brospinal fluid examination, relapsing lymphoma was
suspected on the basis of cerebral magnetic resonance
imaging (MRI) findings. Oncologists prescribed dexa-
methasone 32 mg/day. Symptoms regressed and MRI
findings improved. Four weeks after the initiation of glu-
cocorticoids, excoriations on both legs developed and
antibiotic therapy with cefazolin 6 g/day was given for
10 days. Two weeks later, fever occurred, and sulbac-
tam/ampicillin 3 g/day was given for nine days. Gluco-
corticoid therapy was continued. Swabs taken from the
excoriations and one of five blood cultures were positive
for methicillin-resistant Staphylococcus aureus (MRSA).
Pseudomonas aeruginosa grew on a further excoriation
swab. Since MRSA was found in only one blood culture,
prolonged antibiotic therapy was deemed not to be indi-
cated. Unfortunately, endocarditis was not considered,
and she was discharged without echocardiography. Four
weeks later, she fell, developed a hematoma, and was re-
hospitalized because of a hemorrhagic erysipela. MRSA
grew on a swab from the erysipela. P. aeruginosa grew
in blood cultures and on excoriation swabs of the legs.
Linezolid 1200 mg/day and sulbactam/ampicillin 3 g/day
were started. This time, endocarditis was considered,
and transesophageal echocardiography showed no
thrombus or vegetations on the SO but was highly
suggestive of an aortic valve vegetation (Figure 1). Our
patient died three days later because of septicemia and
multi-organ failure. An autopsy was not performed.
Discussion
The pathogenesis can be explained as follows: Skin
lesions developed as a side effect of glucocorticoids, and
this also favored immunosuppression. The infectious
agents that lastly caused septicemia, multi-organ failure,
death, and probably endocarditis either entered via the
skin or may have derived from the SO, although the evi-
dence for the latter assumption is lacking.
Thrombus formation and infection are rare complica-
tions of ASD occluders, and only six reports of device-
related infection have been published to date [1-5]. Both
thrombi and vegetations on occluders present on echo-
cardiography as shaggy masses typically with multiple
mobile strands. Although in our patient these findings
were not found on echocardiography, the SO might
have served as a nidus for the bacteria. This hypothesis
is substantiated by histological findings of explanted
SOs, showing a chronic inflammatory reaction inside
the occluder [7]. In our patient, who already had experi-
enced an unusually late SO thrombosis, delayed
endothelialization, probably induced by chemotherapy
or glucocorticoids, and thus propensity for bacterial
colonization might have occurred. Unfortunately, these
considerations are only speculative since no pathologic
examination or post-mortem cultures of the device have
Figure 1 A transesophageal echocardiogram shows the left atrium (LA), parts of the mitral valve (MV), the left ventricle (LV), the
ascending aorta (AO), and a thickened aortic cusp (arrow), the last of which is highly suggestive of endocarditis.
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earlier and the aortic valve vegetations detected, cardiac
surgery, including inspection and eventually removal of
the SO, would have been a therapeutic option. Such a
procedure has been chosen in reported cases of endo-
carditis after occluder implantation [1-5,7].
Conclusions
This case shows that, in patients with SO and infections,
clinicians should have a high suspicion for endocarditis.
Echocardiography should be performed early and
repeated if there is bacteremia. To prevent a fatal out-
come, explantation of the SO should be considered,
especially in patients who already had SO-related pro-
blems that suggested delayed endothelialization. Post-
mortem investigations, including bacteriologic studies,
should be carried out in patients with SO in order to
assess the focal and global long-term effects of these
devices.
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